Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (111-120 of 339) with videos related to

Pageof 34
Sort By:
Cancer|December 3, 2005
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemiaAndrea Kuendgen, Mathias Schmid, Richard Schlenk, et al.
Genes, Chromosomes & Cancer|September 8, 2007
Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGHChristina Evers, Manfred Beier, Anne Poelitz, et al.
British Journal of Haematology|May 1, 2020
Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidineCatharina Müller-Thomas, Michael Heider, Guido Piontek, et al.
Blood Cancer Journal|November 14, 2019
Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDSChristina Rautenberg, Ulrich Germing, Sabrina Pechtel, et al.
Cancers|May 14, 2022
Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient ExpectationsAmelie Boquoi, Veronika Rings, Annemarie Mohring, et al.
American Journal of Hematology|May 27, 2015
Deep serum discoveries: SDF-1α and HSA fragments in myelodysplastic syndromesJulia Fröbel, Sonja Hartwig, Sabine Jourdain, et al.
Annals of Hematology|June 25, 2010
Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspectiveFelicitas Kühne, Thomas Mittendorf, Ulrich Germing, et al.
European Journal of Haematology|December 23, 2018
Interaction of increasing ICU survival and admittance policies in patients with hematologic neoplasms: A single center experience with 304 patientsMustafa Kondakci, Marc C Reinbach, Ulrich Germing, et al.
Cancer|March 9, 2010
Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromesFriedrich Wimazal, Ulrich Germing, Michael Kundi, et al.
Annals of Hematology|July 29, 2021
Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patientsJudith Strapatsas, Elena Calina Barbulescu, Michael Lauseker, et al.
Pageof 34

Showing results (111-120 of 339) with videos related to

Sort By:
Pageof 34
Cancer|December 3, 2005
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemiaAndrea Kuendgen, Mathias Schmid, Richard Schlenk, et al.
Genes, Chromosomes & Cancer|September 8, 2007
Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGHChristina Evers, Manfred Beier, Anne Poelitz, et al.
British Journal of Haematology|May 1, 2020
Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidineCatharina Müller-Thomas, Michael Heider, Guido Piontek, et al.
Blood Cancer Journal|November 14, 2019
Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDSChristina Rautenberg, Ulrich Germing, Sabrina Pechtel, et al.
Cancers|May 14, 2022
Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient ExpectationsAmelie Boquoi, Veronika Rings, Annemarie Mohring, et al.
American Journal of Hematology|May 27, 2015
Deep serum discoveries: SDF-1α and HSA fragments in myelodysplastic syndromesJulia Fröbel, Sonja Hartwig, Sabine Jourdain, et al.
Annals of Hematology|June 25, 2010
Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspectiveFelicitas Kühne, Thomas Mittendorf, Ulrich Germing, et al.
European Journal of Haematology|December 23, 2018
Interaction of increasing ICU survival and admittance policies in patients with hematologic neoplasms: A single center experience with 304 patientsMustafa Kondakci, Marc C Reinbach, Ulrich Germing, et al.
Cancer|March 9, 2010
Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromesFriedrich Wimazal, Ulrich Germing, Michael Kundi, et al.
Annals of Hematology|July 29, 2021
Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patientsJudith Strapatsas, Elena Calina Barbulescu, Michael Lauseker, et al.
Pageof 34